Welcome to our dedicated page for West Pharm Svcs news (Ticker: WST), a resource for investors and traders seeking the latest updates and insights on West Pharm Svcs stock.
West Pharmaceutical Services, Inc. (NYSE: WST) provides injectable drug administration solutions and services for pharmaceutical, biotechnology and generic drug customers. Its business includes elastomer-based packaging components such as stoppers, seals and plungers, nonglass containment technologies, auto-injectors and contract services for device manufacturing, assembly, packaging, validation, analytical testing and regulatory support.
News about West commonly covers quarterly results, revenue guidance, Proprietary Products and Contract Manufacturing performance, capacity additions for high-volume injectable therapies, and demand tied to biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. Other recurring developments include dividends, share repurchase authorizations, investor conference participation and governance or executive-transition updates.
West Pharmaceutical Services (NYSE: WST) has announced its participation in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March 23, 2022, at 9:00 a.m. EDT. The virtual event will feature a live audio webcast available in the 'Investors' section of its website. West specializes in high-quality injectable drug administration solutions, generating $2.83 billion in net sales in fiscal year 2021, with a workforce of approximately 10,000 across 50 sites worldwide.
West Pharmaceutical Services (NYSE: WST) has announced that Eric M. Green, the current President and CEO, will also serve as Chair of the Board starting May 24, 2022. He succeeds Patrick Zenner, who is retiring after 20 years. The company highlights Green's successful leadership during the pandemic and his focus on innovative, high-quality products. Additionally, Paolo Pucci has been appointed as the Lead Independent Director of the Board. West generated $2.83 billion in net sales in FY 2021 and employs about 10,000 team members globally.
West Pharmaceutical Services, Inc. (NYSE: WST) has declared a second-quarter 2022 dividend of $0.18 per share, payable on May 4, 2022, to shareholders on record as of April 20, 2022. The company, a leader in innovative injectable solutions, reported $2.83 billion in net sales for fiscal year 2021 and employs approximately 10,000 people across 50 sites globally. West continues to support the effective delivery of life-saving medicines, enhancing shareholder value through consistent dividends.
West Pharmaceutical Services reported its fourth-quarter and full-year 2021 financial results, showcasing significant growth. Q4 net sales reached $730.8 million, a 26% increase, with organic growth at 28.3%. Full-year sales totaled $2.832 billion, up 31.9%. Reported diluted EPS for Q4 was $1.93, a 49.6% rise, and $8.67 for the year, up 89.7%. The company projects 2022 net sales between $3.050 billion and $3.075 billion, with diluted EPS expected between $9.20 and $9.35. They noted strong demand in their Proprietary Products segment and plans for future growth.
West Pharmaceutical Services, a leader in injectable drug administration, will announce its fourth-quarter and full-year 2021 financial results on February 17, 2022, before the market opens. A conference call to discuss these results is scheduled for 9:00 a.m. ET on the same day. Participants can join by calling 877-930-8295 (U.S.) or 253-336-8738 (International), using conference ID 1986145. An archive of the call will be available for review until February 24, 2022. For more information, visit www.westpharma.com.
West Pharmaceutical Services (WST) has entered an exclusive supply and technology agreement with Corning (GLW) to enhance injectable drug delivery systems. This multimillion-dollar partnership seeks to expand Corning’s Valor® Glass technology, promoting advanced packaging solutions for the pharmaceutical industry aimed at improving patient safety and access to treatments. The collaboration combines West’s NovaPure® components with Corning’s Valor Glass, optimizing manufacturing processes and regulatory navigation for biopharma producers.
West Pharmaceutical Services (WST) announced a $0.18 per share dividend for Q1 2022, payable on February 2, 2022, to shareholders on record by January 19, 2022. Additionally, the company's Board of Directors approved a share repurchase program for 2022, allowing the buyback of up to 650,000 shares. This program aims to enhance shareholder value and is expected to conclude by December 31, 2022, following the expiration of a previous buyback.
West Pharmaceutical Services (NYSE: WST) announced its participation in the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 11:15 a.m. EST. The event will be held virtually, allowing investors to access a live audio webcast in the "Investors" section of the company's website. West is a leader in injectable drug solutions, generating over $2.15 billion in sales during fiscal year 2020. With nearly 10,000 employees across 50 sites, West provides over 40 billion components and devices annually.
West Pharmaceutical Services (NYSE: WST) will participate in the Jefferies London Healthcare Conference from November 16-18, 2021, with a Fireside Chat on November 16, 2021, at 5:40 p.m. GMT. The company will also attend the Stephens Investment Conference in Nashville, TN, from December 1-3, 2021, featuring a Fireside Chat on December 3, 2021, at 11:00 a.m. CST. Webcasts for both events will be available on the company's website, with replays accessible for 90 days. West, a leader in injectable solutions, generated over $2.15 billion in sales in FY 2020.
West Pharmaceutical Services reported a strong Q3 2021, with net sales of $706.5 million, a 28.9% increase year-over-year. Reported diluted EPS rose 112% to $2.31. The company raised its full-year net sales guidance to $2.800-$2.810 billion and adjusted diluted EPS guidance to $8.40-$8.50. A quarterly dividend of $0.18 per share was approved, reflecting a 5.9% increase. Sales growth was driven by proprietary products, particularly from the High-Value Product portfolio.